March 2, 2020 / 7:54 AM / a month ago

BRIEF-Medivir: Positive Data From Completed Phase Ia Study With MIV-818 In Patients With Advanced Liver Cancer

March 2 (Reuters) - Medivir AB:

* MEDIVIR PRESENTS POSITIVE DATA FROM THE COMPLETED PHASE IA STUDY WITH MIV-818 IN PATIENTS WITH ADVANCED LIVER CANCER

* PRIMARY OBJECTIVE OF PHASE IA STUDY WAS TO EVALUATE SAFETY AND TOLERABILITY OF MIV-818 IN LIVER CANCER PATIENTS

* A TOTAL OF NINE PATIENTS WITH ADVANCED DISEASE WERE INCLUDED: SIX PATIENTS WITH METASTATIC LIVER CANCER, TWO WITH HEPATOCELLULAR CARCINOMA AND ONE WITH INTRAHEPATIC CHOLANGIOCARCINOMA

* PHARMACOKINETIC ANALYSIS SHOWED THAT PATIENTS WERE EXPOSED ONLY TO LOW LEVELS OF MIV-818 AND TROXACITABINE OUTSIDE OF LIVER, PROVIDING EXPERIMENTAL SUPPORT FOR MIV-818’S LIVER TARGETING

* ADVERSE EVENTS WERE MAINLY MILD AND MORE SERIOUS SIDE EFFECTS OBSERVED WERE REVERSIBLE

* BASED ON AN INDEPENDENT EXPERT ANALYSIS OF LIVER TUMOR GROWTH, FIVE OF NINE PATIENTS WERE ASSESSED TO HAVE STABLE LIVER DISEASE AFTER TREATMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below